Advice

in the absence of a submission from the holder of the marketing authorisation:

elotuzumab (Empliciti®) is not recommended for use within NHSScotland.

Indication under review: In combination with pomalidomide and dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Download detailed advice617KB (PDF)

Download

Medicine details

Medicine name:
elotuzumab (Empliciti)
SMC ID:
SMC2407
Indication:

In combination with pomalidomide and dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy.

Pharmaceutical company
Bristol-Myers Squibb Pharmaceuticals Ltd
BNF chapter
Malignant disease and immunosuppression
Submission type
Non submission
Date advice published
09 August 2021